SGRY: Q2 2026 delivered revenue and EBITDA growth, with guidance reaffirmed and Idaho Falls divestiture boosting margins
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 2.7% year-over-year revenue growth and a 14.7% adjusted EBITDA margin, with strong physician recruitment and reaffirmed full-year guidance. The Idaho Falls Market divestiture is expected to be accretive to EBITDA growth and reduces Medicaid exposure.Original document: Surgery Partners, Inc. [SGRY] Slides Release — Aug. 10 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 2.7% year-over-year revenue growth and a 14.7% adjusted EBITDA margin, with strong physician recruitment and reaffirmed full-year guidance. The Idaho Falls Market divestiture is expected to be accretive to EBITDA growth and reduces Medicaid exposure.
Original document: Surgery Partners, Inc. [SGRY] Slides Release — Aug. 10 2026